Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | CHUK | O15111 | 1/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | PAK4 | O96013 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | MARK3 | P27448 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5973949 | 0.92 | L3MBTL1 (0.70) | L3MBTL1PKMTHRBPLK4CHEK1 | |
| SCHEMBL8447783 | 0.87 | KMT2A (0.64) | L3MBTL1KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL5974915 | 0.83 | KMT2A (0.69) | L3MBTL1PKMTHRBKMT2APOLB | |
| SCHEMBL3069463 | 0.81 | PLAU (0.76) | L3MBTL1PKMKMT2APOLBMEN1 | |
| SCHEMBL5974770 | 0.81 | KMT2A (0.73) | L3MBTL1KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL13878433 | 0.81 | KMT2A (0.76) | THRBKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL7234090 | 0.81 | NPC1 (0.65) | THRBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL1086463 | 0.80 | PARP1 (0.63) | L3MBTL1KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL28031074 | 0.80 | PLAU (0.69) | L3MBTL1PKMKMT2APOLBMEN1 | |
| SCHEMBL7046161 | 0.79 | SIRT2 (0.50) | ROCK2ROCK1KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004016258-A1 | THERAPEUTICAL USE OF GUANYLHYDRAZONES FOR TREATING DISEASES ASSOCIATED WITH DENDRITIC CELL MATURATION | MONDOBIOTECH LABORATORIES ANSTALT (CH) | 2004-02-26 | — | — | WO | claimed |
| US-20030203969-A1 | Pharmaceutically active aromatic guanylhydrazones | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-30 | — | — | US | claimed |
| WO-2003006426-A1 | AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2003-01-23 | — | — | WO | claimed |
| EP-1255541-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-11-13 | — | — | EP | claimed |
| WO-2002000613-A2 | INHIBITORS OF HEPATITIS B VIRUS INFECTION | AXXIMA PHARMACEUTICALS AG (DE) | 2002-01-03 | — | — | WO | claimed |
| WO-2001056553-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-08-09 | — | — | WO | claimed |
| EP-1255541-B1 | AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS | BEVEC DORIAN (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004016258-A1 | THERAPEUTICAL USE OF GUANYLHYDRAZONES FOR TREATING DISEASES ASSOCIATED WITH DENDRITIC CELL MATURATION | MONDOBIOTECH LABORATORIES ANSTALT (CH) | 2004-02-26 | — | — | WO | disclosed |
| EP-1389480-A1 | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation | Mondobiotech Interferon SA (CH) | 2004-02-18 | — | — | EP | disclosed |
| US-20030203969-A1 | Pharmaceutically active aromatic guanylhydrazones | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006426-A1 | AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2003-01-23 | — | — | WO | disclosed |
| EP-1255541-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002000613-A2 | INHIBITORS OF HEPATITIS B VIRUS INFECTION | AXXIMA PHARMACEUTICALS AG (DE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001056553-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203969-A1 | Pharmaceutically active aromatic guanylhydrazones | DHPS, GGPS1, GMPS | L3MBTL1 3998/4885PKM 1478/4885THRB 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.